Literature DB >> 22236679

Stereotactic radiosurgery of brain metastasis from melanoma.

Edward M Marchan1, Jason Sheehan.   

Abstract

Brain metastasis represents the most common intracranial neoplasm in adult patients. Melanoma is the third most frequent cancer histology and consequently comprises a significant portion of brain metastasis patients. Unlike the more frequent lung and breast cancers, melanoma represents a particularly challenging entity because of its radioresistant nature. Stereotactic radiosurgery appears to overcome the inherent radioresistance of brain metastasis from melanoma and, thereby, affords a high rate of local tumor control. Reports from leading centers indicate a favorable benefit to risk profile for radiosurgery in melanoma patients. Local tumor control after radiosurgery generally exceeds 80%, and neurological complications as a result of radiosurgery are infrequent. A higher performance status and lower intracranial tumor burden in melanoma patients at the time of radiosurgery are associated with longer survival. Radiosurgery may be used in conjunction upfront with radiotherapy, resection, and chemotherapy or as a salvage therapy in selected melanoma patients. Careful radiological and neurological follow-up is required to assess local tumor control and distant intracranial disease progression. Further clinical studies will be required to better define the role of upfront and salvage radiosurgery in selected cohorts of patients with brain metastasis from melanoma. However, it appears likely that radiosurgery will play an expanded role in the overall management of these patients.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22236679     DOI: 10.1159/000331191

Source DB:  PubMed          Journal:  Prog Neurol Surg        ISSN: 0079-6492


  3 in total

Review 1.  Cranial stereotactic radiosurgery: current status of the initial paradigm shifter.

Authors:  Jason P Sheehan; Chun-Po Yen; Cheng-Chia Lee; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

2.  IL-6 receptor is a possible target against growth of metastasized lung tumor cells in the brain.

Authors:  Mami Noda; Yukiko Yamakawa; Naoya Matsunaga; Satoko Naoe; Taishi Jodoi; Megumi Yamafuji; Nozomi Akimoto; Norihiro Teramoto; Kyota Fujita; Shigehiro Ohdo; Haruo Iguchi
Journal:  Int J Mol Sci       Date:  2012-12-27       Impact factor: 5.923

3.  Immune Checkpoint Inhibitors and Survival Outcomes in Brain Metastasis: A Time Series-Based Meta-Analysis.

Authors:  Xingjiang Hu; Hui Yu; Yunliang Zheng; Qiao Zhang; Meihua Lin; Jialei Wang; Yunqing Qiu
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.